New study examines benefits of continuous glucose monitoring (CGM) in people with type 2 diabetes (T2D) using glucagon-like ...

The Diabetes Technology Meeting is a highly regarded ... Mark Tapsak, PhD, Vice President of Sensor Technology, will deliver the oral presentation, titled “The Technology Behind Continuous ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation ...

Presentation details are as follows; times noted are Eastern time: Poster Title: Evaluating Acceptance of a Continuous Blood Glucose Monitor for Insulin-Requiring People with Diabetes Poster ...

Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of ...

one poster presentation, and host an oral symposium at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December ...

DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of ...

and generate insights that improve care for people with diabetes." Key studies include an oral presentation exploring equitable strategies to increase CGM adoption by people with T2D, expanding ...

ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection ...